Loading…

Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery

After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal (MF) and multicentric (MC) tumors have been considered a contraindication for this...

Full description

Saved in:
Bibliographic Details
Published in:World journal of surgical oncology 2006-11, Vol.4 (1), p.79-79, Article 79
Main Authors: Ferrari, Alberta, Dionigi, Paolo, Rovera, Francesca, Boni, Luigi, Limonta, Giorgio, Garancini, Silvana, De Palma, Diego, Dionigi, Gianlorenzo, Vanoli, Cristiana, Diurni, Mario, Carcano, Giulio, Dionigi, Renzo
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303
cites cdi_FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303
container_end_page 79
container_issue 1
container_start_page 79
container_title World journal of surgical oncology
container_volume 4
creator Ferrari, Alberta
Dionigi, Paolo
Rovera, Francesca
Boni, Luigi
Limonta, Giorgio
Garancini, Silvana
De Palma, Diego
Dionigi, Gianlorenzo
Vanoli, Cristiana
Diurni, Mario
Carcano, Giulio
Dionigi, Renzo
description After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal (MF) and multicentric (MC) tumors have been considered a contraindication for this technique due to the possible incidence of a higher false-negative rate. This prospective study evaluates the lymphatic drainage from different tumoral foci of the breast and assesses the accuracy of SLNB in MF-MC breast cancer. Patients with preoperative diagnosis of MF or MC infiltrating and clinically node-negative (cN0) breast carcinoma were enrolled in this study. Two consecutive groups of patients underwent SLN mapping using a different site of injection of the radioisotope tracer: a) "2ID" Group received two intradermal (i.d.) injections over the site of the two dominant neoplastic nodules. A lymphoscintigraphic study was performed after each injection to evaluate the route of lymphatic spreading from different sites of the breast. b) "A" Group had periareolar (A) injection followed by a conventional lymphoscintigraphy. At surgery, both radioguided SLNB (with frozen section exam) and subsequent AD were planned, regardless the SLN status. A total 31 patients with MF (n = 12) or MC (n = 19) invasive, cN0 cancer of the breast fulfil the selection criteria. In 2 i.d. Group (n = 15) the lymphoscintigraphic study showed the lymphatic pathways from two different sites of the breast which converged into one major lymphatic trunk affering to the same SLN(s) in 14 (93.3%) cases. In one (6.7%) MC cancer two different pathways were found, each of them affering to a different SLN. In A Group (n = 16) lymphoscintigraphy showed one (93.7%) or two (6.3%) lymphatic channels, each connecting areola with one or more SLN(s). Identification rate of SLN was 100% in both Groups. Accuracy of frozen section exam on SLN was 96.8% (1 case of micrometastasis was missed). SLN was positive in 13 (41.9%) of 31 patients, including 4 cases (30.7%) of micrometastasis. In 7 of 13 (53.8%) patients the SLN was the only site of axillary metastasis. SLNB accuracy was 96.8% (30 of 31), sensitivity 92.8 (13 of 14), and false-negative rate 7.1% (1 of 14). Since the case of skip metastasis was identified by the surgeon intraoperatively, it would have been no impact in the clinical practice. Our lymphoscintigraphic study shows that axillary SLN represents the whole breast regardless of tumor locat
doi_str_mv 10.1186/1477-7819-4-79
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d9ed495c7b5243409dc3c65f518c37e6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d9ed495c7b5243409dc3c65f518c37e6</doaj_id><sourcerecordid>68196800</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303</originalsourceid><addsrcrecordid>eNqFkstrFTEUxgdRbK1uXUpW7qYmk8lrI5Tio1Bxo-twJo_blJnkmswI898390HtRcRVwne-_PhyzmmatwRfEiL5B9IL0QpJVNu3Qj1rzh-F50_uZ82rUu4x7ihl9GVzRgQhvGPyvCnflnEOPhkYw7wiiBZNO8W4OOdg9lp2KKYZmVQlCNEGA3NIsSCfMirVGKIb0bhO27tqtA4NIW3LikJEQ3ZQ6lOIxlXvkjcur6-bFx7G4t4cz4vm5-dPP66_trffv9xcX922Q8-kaofBKYblIIitwYEJ2nXMUuElB9H5gYDEFDD2HoOrD7gCbplyXe_BGorpRXNz4NoE93qbwwR51QmC3gspbzTk-tXRaauc7RUzYmBdT3usKsBw5hmRhgrHK-vjgbVdhsnZfXtgPIGeVmK405v0WxPOWc9oBVwdALU5_wCcVkya9G6AejdA3WuhKuP9MUROvxZXZj2FYtw4QnRpKZpXJ5cY_9dIlBIKd7IaLw9Gk1Mp2fnHQATr3YL9HeHd0z78sR83ij4ASwnPcQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19979028</pqid></control><display><type>article</type><title>Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery</title><source>PubMed Central Free</source><creator>Ferrari, Alberta ; Dionigi, Paolo ; Rovera, Francesca ; Boni, Luigi ; Limonta, Giorgio ; Garancini, Silvana ; De Palma, Diego ; Dionigi, Gianlorenzo ; Vanoli, Cristiana ; Diurni, Mario ; Carcano, Giulio ; Dionigi, Renzo</creator><creatorcontrib>Ferrari, Alberta ; Dionigi, Paolo ; Rovera, Francesca ; Boni, Luigi ; Limonta, Giorgio ; Garancini, Silvana ; De Palma, Diego ; Dionigi, Gianlorenzo ; Vanoli, Cristiana ; Diurni, Mario ; Carcano, Giulio ; Dionigi, Renzo</creatorcontrib><description>After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal (MF) and multicentric (MC) tumors have been considered a contraindication for this technique due to the possible incidence of a higher false-negative rate. This prospective study evaluates the lymphatic drainage from different tumoral foci of the breast and assesses the accuracy of SLNB in MF-MC breast cancer. Patients with preoperative diagnosis of MF or MC infiltrating and clinically node-negative (cN0) breast carcinoma were enrolled in this study. Two consecutive groups of patients underwent SLN mapping using a different site of injection of the radioisotope tracer: a) "2ID" Group received two intradermal (i.d.) injections over the site of the two dominant neoplastic nodules. A lymphoscintigraphic study was performed after each injection to evaluate the route of lymphatic spreading from different sites of the breast. b) "A" Group had periareolar (A) injection followed by a conventional lymphoscintigraphy. At surgery, both radioguided SLNB (with frozen section exam) and subsequent AD were planned, regardless the SLN status. A total 31 patients with MF (n = 12) or MC (n = 19) invasive, cN0 cancer of the breast fulfil the selection criteria. In 2 i.d. Group (n = 15) the lymphoscintigraphic study showed the lymphatic pathways from two different sites of the breast which converged into one major lymphatic trunk affering to the same SLN(s) in 14 (93.3%) cases. In one (6.7%) MC cancer two different pathways were found, each of them affering to a different SLN. In A Group (n = 16) lymphoscintigraphy showed one (93.7%) or two (6.3%) lymphatic channels, each connecting areola with one or more SLN(s). Identification rate of SLN was 100% in both Groups. Accuracy of frozen section exam on SLN was 96.8% (1 case of micrometastasis was missed). SLN was positive in 13 (41.9%) of 31 patients, including 4 cases (30.7%) of micrometastasis. In 7 of 13 (53.8%) patients the SLN was the only site of axillary metastasis. SLNB accuracy was 96.8% (30 of 31), sensitivity 92.8 (13 of 14), and false-negative rate 7.1% (1 of 14). Since the case of skip metastasis was identified by the surgeon intraoperatively, it would have been no impact in the clinical practice. Our lymphoscintigraphic study shows that axillary SLN represents the whole breast regardless of tumor location within the parenchyma. The high accuracy of SLNB in MF and MC breast cancer demonstrates, according with the results of other series published in the literature, that both MF and MC tumors do not represent a contraindication for SLNB anymore.</description><identifier>ISSN: 1477-7819</identifier><identifier>EISSN: 1477-7819</identifier><identifier>DOI: 10.1186/1477-7819-4-79</identifier><identifier>PMID: 17116258</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><ispartof>World journal of surgical oncology, 2006-11, Vol.4 (1), p.79-79, Article 79</ispartof><rights>Copyright © 2006 Ferrari et al; licensee BioMed Central Ltd. 2006 Ferrari et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303</citedby><cites>FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665453/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665453/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17116258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferrari, Alberta</creatorcontrib><creatorcontrib>Dionigi, Paolo</creatorcontrib><creatorcontrib>Rovera, Francesca</creatorcontrib><creatorcontrib>Boni, Luigi</creatorcontrib><creatorcontrib>Limonta, Giorgio</creatorcontrib><creatorcontrib>Garancini, Silvana</creatorcontrib><creatorcontrib>De Palma, Diego</creatorcontrib><creatorcontrib>Dionigi, Gianlorenzo</creatorcontrib><creatorcontrib>Vanoli, Cristiana</creatorcontrib><creatorcontrib>Diurni, Mario</creatorcontrib><creatorcontrib>Carcano, Giulio</creatorcontrib><creatorcontrib>Dionigi, Renzo</creatorcontrib><title>Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery</title><title>World journal of surgical oncology</title><addtitle>World J Surg Oncol</addtitle><description>After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal (MF) and multicentric (MC) tumors have been considered a contraindication for this technique due to the possible incidence of a higher false-negative rate. This prospective study evaluates the lymphatic drainage from different tumoral foci of the breast and assesses the accuracy of SLNB in MF-MC breast cancer. Patients with preoperative diagnosis of MF or MC infiltrating and clinically node-negative (cN0) breast carcinoma were enrolled in this study. Two consecutive groups of patients underwent SLN mapping using a different site of injection of the radioisotope tracer: a) "2ID" Group received two intradermal (i.d.) injections over the site of the two dominant neoplastic nodules. A lymphoscintigraphic study was performed after each injection to evaluate the route of lymphatic spreading from different sites of the breast. b) "A" Group had periareolar (A) injection followed by a conventional lymphoscintigraphy. At surgery, both radioguided SLNB (with frozen section exam) and subsequent AD were planned, regardless the SLN status. A total 31 patients with MF (n = 12) or MC (n = 19) invasive, cN0 cancer of the breast fulfil the selection criteria. In 2 i.d. Group (n = 15) the lymphoscintigraphic study showed the lymphatic pathways from two different sites of the breast which converged into one major lymphatic trunk affering to the same SLN(s) in 14 (93.3%) cases. In one (6.7%) MC cancer two different pathways were found, each of them affering to a different SLN. In A Group (n = 16) lymphoscintigraphy showed one (93.7%) or two (6.3%) lymphatic channels, each connecting areola with one or more SLN(s). Identification rate of SLN was 100% in both Groups. Accuracy of frozen section exam on SLN was 96.8% (1 case of micrometastasis was missed). SLN was positive in 13 (41.9%) of 31 patients, including 4 cases (30.7%) of micrometastasis. In 7 of 13 (53.8%) patients the SLN was the only site of axillary metastasis. SLNB accuracy was 96.8% (30 of 31), sensitivity 92.8 (13 of 14), and false-negative rate 7.1% (1 of 14). Since the case of skip metastasis was identified by the surgeon intraoperatively, it would have been no impact in the clinical practice. Our lymphoscintigraphic study shows that axillary SLN represents the whole breast regardless of tumor location within the parenchyma. The high accuracy of SLNB in MF and MC breast cancer demonstrates, according with the results of other series published in the literature, that both MF and MC tumors do not represent a contraindication for SLNB anymore.</description><issn>1477-7819</issn><issn>1477-7819</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkstrFTEUxgdRbK1uXUpW7qYmk8lrI5Tio1Bxo-twJo_blJnkmswI898390HtRcRVwne-_PhyzmmatwRfEiL5B9IL0QpJVNu3Qj1rzh-F50_uZ82rUu4x7ihl9GVzRgQhvGPyvCnflnEOPhkYw7wiiBZNO8W4OOdg9lp2KKYZmVQlCNEGA3NIsSCfMirVGKIb0bhO27tqtA4NIW3LikJEQ3ZQ6lOIxlXvkjcur6-bFx7G4t4cz4vm5-dPP66_trffv9xcX922Q8-kaofBKYblIIitwYEJ2nXMUuElB9H5gYDEFDD2HoOrD7gCbplyXe_BGorpRXNz4NoE93qbwwR51QmC3gspbzTk-tXRaauc7RUzYmBdT3usKsBw5hmRhgrHK-vjgbVdhsnZfXtgPIGeVmK405v0WxPOWc9oBVwdALU5_wCcVkya9G6AejdA3WuhKuP9MUROvxZXZj2FYtw4QnRpKZpXJ5cY_9dIlBIKd7IaLw9Gk1Mp2fnHQATr3YL9HeHd0z78sR83ij4ASwnPcQ</recordid><startdate>20061120</startdate><enddate>20061120</enddate><creator>Ferrari, Alberta</creator><creator>Dionigi, Paolo</creator><creator>Rovera, Francesca</creator><creator>Boni, Luigi</creator><creator>Limonta, Giorgio</creator><creator>Garancini, Silvana</creator><creator>De Palma, Diego</creator><creator>Dionigi, Gianlorenzo</creator><creator>Vanoli, Cristiana</creator><creator>Diurni, Mario</creator><creator>Carcano, Giulio</creator><creator>Dionigi, Renzo</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20061120</creationdate><title>Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery</title><author>Ferrari, Alberta ; Dionigi, Paolo ; Rovera, Francesca ; Boni, Luigi ; Limonta, Giorgio ; Garancini, Silvana ; De Palma, Diego ; Dionigi, Gianlorenzo ; Vanoli, Cristiana ; Diurni, Mario ; Carcano, Giulio ; Dionigi, Renzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferrari, Alberta</creatorcontrib><creatorcontrib>Dionigi, Paolo</creatorcontrib><creatorcontrib>Rovera, Francesca</creatorcontrib><creatorcontrib>Boni, Luigi</creatorcontrib><creatorcontrib>Limonta, Giorgio</creatorcontrib><creatorcontrib>Garancini, Silvana</creatorcontrib><creatorcontrib>De Palma, Diego</creatorcontrib><creatorcontrib>Dionigi, Gianlorenzo</creatorcontrib><creatorcontrib>Vanoli, Cristiana</creatorcontrib><creatorcontrib>Diurni, Mario</creatorcontrib><creatorcontrib>Carcano, Giulio</creatorcontrib><creatorcontrib>Dionigi, Renzo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>World journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferrari, Alberta</au><au>Dionigi, Paolo</au><au>Rovera, Francesca</au><au>Boni, Luigi</au><au>Limonta, Giorgio</au><au>Garancini, Silvana</au><au>De Palma, Diego</au><au>Dionigi, Gianlorenzo</au><au>Vanoli, Cristiana</au><au>Diurni, Mario</au><au>Carcano, Giulio</au><au>Dionigi, Renzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery</atitle><jtitle>World journal of surgical oncology</jtitle><addtitle>World J Surg Oncol</addtitle><date>2006-11-20</date><risdate>2006</risdate><volume>4</volume><issue>1</issue><spage>79</spage><epage>79</epage><pages>79-79</pages><artnum>79</artnum><issn>1477-7819</issn><eissn>1477-7819</eissn><abstract>After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal (MF) and multicentric (MC) tumors have been considered a contraindication for this technique due to the possible incidence of a higher false-negative rate. This prospective study evaluates the lymphatic drainage from different tumoral foci of the breast and assesses the accuracy of SLNB in MF-MC breast cancer. Patients with preoperative diagnosis of MF or MC infiltrating and clinically node-negative (cN0) breast carcinoma were enrolled in this study. Two consecutive groups of patients underwent SLN mapping using a different site of injection of the radioisotope tracer: a) "2ID" Group received two intradermal (i.d.) injections over the site of the two dominant neoplastic nodules. A lymphoscintigraphic study was performed after each injection to evaluate the route of lymphatic spreading from different sites of the breast. b) "A" Group had periareolar (A) injection followed by a conventional lymphoscintigraphy. At surgery, both radioguided SLNB (with frozen section exam) and subsequent AD were planned, regardless the SLN status. A total 31 patients with MF (n = 12) or MC (n = 19) invasive, cN0 cancer of the breast fulfil the selection criteria. In 2 i.d. Group (n = 15) the lymphoscintigraphic study showed the lymphatic pathways from two different sites of the breast which converged into one major lymphatic trunk affering to the same SLN(s) in 14 (93.3%) cases. In one (6.7%) MC cancer two different pathways were found, each of them affering to a different SLN. In A Group (n = 16) lymphoscintigraphy showed one (93.7%) or two (6.3%) lymphatic channels, each connecting areola with one or more SLN(s). Identification rate of SLN was 100% in both Groups. Accuracy of frozen section exam on SLN was 96.8% (1 case of micrometastasis was missed). SLN was positive in 13 (41.9%) of 31 patients, including 4 cases (30.7%) of micrometastasis. In 7 of 13 (53.8%) patients the SLN was the only site of axillary metastasis. SLNB accuracy was 96.8% (30 of 31), sensitivity 92.8 (13 of 14), and false-negative rate 7.1% (1 of 14). Since the case of skip metastasis was identified by the surgeon intraoperatively, it would have been no impact in the clinical practice. Our lymphoscintigraphic study shows that axillary SLN represents the whole breast regardless of tumor location within the parenchyma. The high accuracy of SLNB in MF and MC breast cancer demonstrates, according with the results of other series published in the literature, that both MF and MC tumors do not represent a contraindication for SLNB anymore.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>17116258</pmid><doi>10.1186/1477-7819-4-79</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1477-7819
ispartof World journal of surgical oncology, 2006-11, Vol.4 (1), p.79-79, Article 79
issn 1477-7819
1477-7819
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d9ed495c7b5243409dc3c65f518c37e6
source PubMed Central Free
title Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A04%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multifocality%20and%20multicentricity%20are%20not%20contraindications%20for%20sentinel%20lymph%20node%20biopsy%20in%20breast%20cancer%20surgery&rft.jtitle=World%20journal%20of%20surgical%20oncology&rft.au=Ferrari,%20Alberta&rft.date=2006-11-20&rft.volume=4&rft.issue=1&rft.spage=79&rft.epage=79&rft.pages=79-79&rft.artnum=79&rft.issn=1477-7819&rft.eissn=1477-7819&rft_id=info:doi/10.1186/1477-7819-4-79&rft_dat=%3Cproquest_doaj_%3E68196800%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b4589-bbe9508b71d023a573225d37f86a72fb1a803a00ff0ae58969a6d59e24fadc303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19979028&rft_id=info:pmid/17116258&rfr_iscdi=true